中汽協:內地8月新能源車銷量按年升27% 首八個月漲39.2%
中汽協公布,內地8月份新能源車產銷分別完成84.3萬及84.6萬輛,按月各升4.7%及8.5%,按年分別增長22%及27%,市場佔有率達32.8%。
期內,內地新能源車國內銷量75.6萬輛,按月增長11.4%,按年升29.7%;新能源車出口9萬輛,按月跌11.2%,按年增長8.1%。
至於首八個月內地新能源車產銷分別完成543.4萬及537.4萬輛,按年分別增長36.9%及39.2%,市場佔有率達29.5%。
首八個月內地新能源車國內銷量464.7萬輛,按年升32%;新能源車出口72.7萬輛,按年增長1.1倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.